Tempus AI stock
Price history
+5.39% over the period1 year: from $67.94 (November 13, 2025) to $71.60 (November 13, 2026), +5.39%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $71.60 |
| October 30, 2026 | $72.22 |
| September 30, 2026 | $81.90 |
| August 31, 2026 | $63.05 |
| July 31, 2026 | $43.87 |
| June 30, 2026 | $57.93 |
| May 29, 2026 | $50.47 |
| April 30, 2026 | $55.48 |
| March 31, 2026 | $45.22 |
| February 27, 2026 | $53.25 |
| January 30, 2026 | $59.82 |
| December 31, 2025 | $59.05 |
| November 28, 2025 | $77.93 |
| November 13, 2025 | $67.94 |
At a glance
The company
Healthcare technology company offering diagnostic testing, clinical applications, and AI-powered analytics for precision medicine
Latest results
Quarter to September 30, 2026 · EPS $0.07 (estimate $0.01)
TickerLandia's take on Tempus AI
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−19.63% from the 52-week high
Analysts · 20 analysts
Average target$89.56+25.08% vs. price
Buy 10 · Hold 10 · Sell 0 · Buy
TickerLandia Fingerprint: Tempus AI
Compared with similar companies: very low earnings stability, very high risk, and very high price.
Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high88
How much it costs relative to what it produces.
Metric Value Position in group Price/book 26.0 94 Price/sales 8.65 83 Profitabilitylow22
How much it earns on revenue and capital.
Metric Value Position in group ROE −37.6% 8 ROA −7.4% 3 Operating margin −18.5% 6 Gross margin 64.5% 90 Net margin −12.5% 3 Earnings stabilityvery low4
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 36.2% 6 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 2 Growthhigh63
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +58.29% 94 Revenue growth (year over year) +23.10% 90 Earnings growth (year over year) −112.00% 4 Financial strengthlow32
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −3.52 4 Current ratio 2.61 88 Debt/equitycounts in reverse: lower means more financial strength 2.86 6 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong81
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +5.39% 38 Relative strength (3 months) +36.02% 99 Relative strength (6 months) +53.57% 96 Distance from 200-day average +24.63% 91 Riskvery high89
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 46.7% 82 Volatility (60 days) 88.8% 96 Beta (1 year) 2.44 90
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Tempus AI is pricier than similar companies
Tempus AI's Price/book: 26.0, +297% against the median of a group of 7 similar companies (6.57).
Compared with 7 similar companies
| Metric | Tempus AI | Position in the group | Band |
|---|---|---|---|
| Operating margin | -18.5% | Middle | |
| ROE | -37.6% | Low | |
| Debt/equity | 2.86 | High | |
| Price/book | 26.0 | High | |
| Net margin | -12.5% | Low |
Grey band: the middle half of the group; tick: the median; dot: Tempus AI. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$382.49M
Latest quarter · Q2 2026
Net income
$5.64M
Latest quarter · Q2 2026
Quarterly net margin
1.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $13.06B
- EPS
- -$1.06
- Volume
- 5.31M
- Daily trading
- €427.94M
- Dividend yield
- 0.00%
How Tempus AI is changing
All resultsRevenue grew 46.6% a year on average over the last 5 years
Operating margin rose from −83.9% to −19.4%
Shares outstanding up 177.9% in 5 years
Returns
Tempus AI returns
$1,000 invested in Tempus AI 1 year ago, on November 13, 2025, would be worth $1,054 today: +5.39% in total, +5.39% per year. This is the price return only: dividends are excluded.
| Period | Tempus AI | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +4.95% | −3.12% | $1,050 |
| 6 months | +55.99% | +1.58% | $1,560 |
| Year to date | +21.25% | +10.46% | $1,213 |
| 1 year | +5.39% | +12.23% | $1,054 |
Over the last 6 months it has done better than 90% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Tempus AI: technical analysis
Tempus AI shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 30.7% below its all-time closing high ($103.25, October 8, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 47
- Between 30 and 70
- vs 200-session average
- +24.63%
Support and resistance
Price areas where Tempus AI has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$79.37+10.85%2 touches, last on December 8, 2025
- Resistance$74.10+3.49%3 touches, last on August 21, 2026
- Last price$71.60
- Support$62.75−12.36%7 touches, last on November 5, 2026
- Support$56.23−21.47%7 touches, last on September 14, 2026
- Support$48.59−32.14%7 touches, last on August 18, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 2.44
- Volatility (60 sessions, annualised)
- 88.8%
- Largest fall in the last year
- −46.68%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Tempus AI and its competitors
With revenue of $1.3 billion in the fiscal year ended December 2025, Tempus AI operates its Tempus platform, which links clinician workflows with laboratory diagnostics, analytics and a repository of multimodal data. Its diagnostic offering includes next-generation sequencing tests, large-panel solid tumor and hematologic assays, pharmacogenomic testing for psychiatric conditions and genetic tests for inherited conditions. The group also licenses de-identified clinical, molecular and imaging datasets, offers clinical trial matching and develops software such as Lens, Next and Algos for life sciences research and diagnostics.
- Headquarters
- Chicago, United States
- Employees
- 3,800
- Founded
- 2015
- Chief executive
- Eric Lefkofsky
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Tempus AITEM | $13.06B | -18.5% | — | +55.99% |
| DoximityDOCS | $5.95B | 27.1% | 46.3 | +42.54% |
| Veeva SystemsVEEV | $48.82B | 29.9% | 49.4 | +93.62% |
| Pro MedicusPME | $14.57B | 74.9% | 81.4 | +65.15% |
| M32413 | $7.61B | 19.5% | 26.5 | +34.35% |
| XtalPi Holdings2228 | $3B | -124.6% | — | −32.46% |
Same industry or related industries, similar size. Compare Tempus AI with its competitors · Full profile
